研究業績
原著論文
2025
Tsubota M, Sasaki K, Shin E, Okamura Y, Nishimura A, Yamagata A, Nonaka Y, Sekiguchi F, Tomono Y, Nishibori M, Okada T, Toyooka N, Kawabata A.
HMGB1 derived from macrophages and enteric glial cells contributes to the butyrate-induced colonic hypersensitivity in mice.
Eur J Pharmacol. , 177660, 2025.
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.
Metolazone and azosemide, clinically utilized diuretics, exhibit inhibitory activity for glyoxalase I.
Biotechnol Appl Biochem. , e2760, 2025.
Hatipoglu OF, Nishinaka T, Yaykasli KO, Mori S, Watanabe M, Toyomura T, Nishibori M, Hirohata S, Wake H, Takahashi H.
Histidine-rich glycoprotein inhibits TNF-α-induced tube formation in human vascular endothelial cells.
Front Pharmacol. , 16: 1561628, 2025.
Takahashi Y, Htwe SS, Wang D, Wake H, Yata M, Tomonobu N, Kinoshita R, Sakaguchi M, Nishibori M.
Antithrombin regulates neutrophil activities through the stimulation of C-type lectin family 1A.
Blood VTH. , 2(1):100032, 2025.
2024
Hisaoka-Nakashima K, Takeuchi Y, Saito Y, Shimoda T, Nakamura Y, Wang D, Liu K, Nishibori M, Morioka N.
Glucocorticoids induce HMGB1 release in primary cultured rat cortical microglia.
Neuroscience , 560:56-66, 20024.
Ma S, Nakamura Y, Kochi T, Uemoto S, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Morioka N.
Perineural treatment with high mobility group box-1 monoclonal antibody prevents initiation of pain-like behaviors in female mice with trigeminal neuropathy.
Biol Pharm Bull. , 47(1):221-226, 2024.
Gao S, Wang D, Liu K, Tomono Y, Fu L, Gao Y, Takahashi Y, Yata M, Nishibori M.
Anti-HMGB1 mAb therapy reduces epidural hematoma injury.
Int J Mol Sci. , 25(11): 5889, 2024.
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.
Cationic ribosomal proteins can inhibit pro-inflammatory action stimulated by LPS+HMGB1 and are hindered by advanced glycation end products.
Biotechnol Appl Biochem. , 71: 264-271, 2024.
2023
Nishinaka T, Omer Faruk H, Wake H, Watanabe M, Toyomura T, Mori S, Nishibori M, Takahashi H.
Different modulation of STING/TBK1/IRF3 signaling by advanced glycation end products.
Arch Biochem Biophys. , 750:109808, 2023.
Murata H, Phoo MTZ, Ochi T, Tomonobu N, Yamamoto KI, Kinoshita R, Miyazaki I, Nishibori M, Asanuma M, Sakaguchi M.
Phosphorylated SARM1 is involved in the pathological process of rotenone-induced neurodegeneration.
J Biochem. , 174(6):533-548, 2023.
Kitaoka S, Tomohiro A, Ukeshima S, Liu K, Wake H, Kimura SH, Yamamoto Y, Nishibori M, Furuyashiki T.
Repeated social defeat stress induces HMGB1 nuclear export in prefrontal neurons, leading to social avoidance in mice.
Cells , 12(13):1789, 2023.
Toyomura T, Watanabe M, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.
Glycolaldehyde‑derived advanced glycation end products promote macrophage proliferation via the JAK‑STAT signaling pathway.
Mol Biol Rep. , 50(7):5849-5858, 2023.
Goyama T, Fujii Y, Muraoka G, Nakatani T, Ousaka D, Imai Y, Kuwada N, Tsuji T, Shuku T, Uchida HA, Nishibori M, Oozawa S, Kasahara S.
Comprehensive hemocompatibility analysis on the application of diamond-like carbon to ePTFE artificial vascular prosthesis.
Sci Rep. ,13: 8386, 2023.
Dai SJ, Shao YY, Zheng Y, Sun JY, Li ZS, Shi JY, Yan MQ, Qiu XY, Xu CL, Cho WS, Nishibori M, Yi S, Park SB, Wang Y, Chen Z.
Inflachromene attenuates seizure severity in mouse epilepsy models via inhibiting HMGB1 translocation.
Acta Pharmacol Sin. , 44(9):1737-1747, 2023.
Qiao H, Morioka Y, Wang D, Liu K, Gao S, Wake H, Ousaka D, Teshigawara K, Mori S, Nishibori M.
Protective effects of an anti-4-HNE monoclonal antibody against liver injury and lethality of endotoxemia in mice.
Eur J Pharmacol. , 175702, 2023.
Kawanoue N, Kuroda K, Yasuda H, Oiwa M, Suzuki S, Wake H, Hosoi H, Nishibori M, Morimatsu H.
Consistently low levels of histidine-rich glycoprotein as a new prognostic biomarker for sepsis: a multicenter prospective observational study.
PLOS ONE , 18(3):e0283426, 2023.
Hatipoglu OF, Nishinaka T, Nishibori M, Watanabe M, Toyomura T, Mori S, Yaykasli KO, Wake H, Takahashi H.
Histamine promotes angiogenesis through a histamine H1 receptor-PKC-VEGF-mediated pathway in human endothelial cells.
J Pharmacol Sci. , 151(4): 177-186, 2023.
Namba T, Yashiro M, Fujii Y, Tsuge M, Liu K, Nishibori M, Tsukahara H.
Decreased levels of histidine-rich glycoprotein and increased levels of high-mobility group box 1 are risk factors for refractory Kawasaki disease.
Mod Rheumatol., 33(3): 599-607, 2023.
2022
Gao S, Liu K, Ku W, Wang D, Wake H, Qiao H, Teshigawara K, Nishibori M.
Histamine induced high mobility group box-1 release from vascular endothelial cells through H1 receptor.
Front Immunol., 13:930683, 2022.
Wang D, Ousaka D, Qiao H, Wang Z, Zhao K, Gao S, Liu K, Teshigawara K, Takada K, Nishibori M.
Treatment of marmoset intracerebral hemorrhage with humanized anti-HMGB1 mAb.
Cells., 11(19): 2970, 2022.
Nishinaka T, Hatipoglu OF, Wake H, Watanabe M, Toyomura T, Mori S, Nishibori M, Takahashi H.
Glycolaldehyde-derived advanced glycation end products suppress STING/TBK1/IRF3 signaling via CD36.
Life Sci. , 310:121116, 2022.
Du Y, Xu CL, Yu J, Liu K, Lin SD, Hu TT, Qu FH, Guo F, Lou GD, Nishibori M, Hu WW, Chen Z, Zhang SH.
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain.
J Headache Pain, 23(1):102, 2022.
Tomonobu N, Kinoshita R, Wake H, Inoue Y, Ruma IMW, Suzawa K, Gohara Y, Komalasari NLGY, Jiang F, Murata H, Yamamoto K, Sumardika IW, Chen Y, Futami J, Yamauchi A, Kuribayashi F, Kondo E, Toyooka S, Nishibori M, Sakaguchi M.
Histidine-rich glycoprotein suppresses the S100A8/A9-mediated organotropic metastasis of melanoma cells.
Int J Mol Sci., 23(18): 10300, 2022.
Watanabe M, Toyomura T, Ikegami R, Suwaki Y, Sada M, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.
Nordihydroguaiaretic acid inhibits glyoxalase I, and causes the accumulation of methylglyoxal followed by cell-growth inhibition.
Mol Biol Rep., 49(11): 10499-10507, 2022.
Ousaka D, Nishibori M.
Is hemolysis a novel therapeutic target in COVID-19?
Front Immunol., 13: 956671, 2022.
Nishibori M. (Commemorative Review Article for the 14th Ebashi Setsuro Award)
Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19.
J Pharmacol Sci., 150(1): 9-20, 2022.
Hisaoka-Nakashima K, Ohata K, Yoshimoto N, Tokuda S, Yoshii N, Nakamura Y, Wang D, Liu K, Wake H, Yoshida T, Ago Y, Hashimoto K, Nishibori M, Morioka N.
High-mobility group box 1-mediated hippocampal microglial activation induces cognitive impairment in mice with neuropathic pain.
Exp Neurol. , 335:114146, 2022.
Kamiya M, Mizoguchi F, Kawahata K, Wang D, Nishibori M, Day J, Louis C, Wicks LP, Kohsaka H, Yasuda S.
Targeting necroptosis in muscle fibers ameliorates inflammatory myopathies.
Nat Commun ., 13(1): 166, 2022.
Sato F, Nakamura Y, Ma S, Kochi T, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Morioka N.
Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson’s disease.
Biomed Pharmacother ., 145: 112479, 2022.
Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A.
Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplation treatment: Evidence from clinical and preclinical studies.
J Pharmacol Sci ., 148(3): 315-325, 2022.
Domoto R, Sekiguchi F, Kamaguchi R, Iemura M, Yamanishi H, Tsubota M, Wang D, Nishibori M, Kawabata A.
Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy.
J Pharmacol Sci. , 148(1): 156-161, 2022.
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.
Identification of ribosomal protein L9 as a novel regulator of proinflammatory damage-associated molecular pattern molecules.
Mol Biol Rep. , 49(4): 2831-3838, 2022.
2021
Gao S, Nishibori M.
Multiple roles of histidine-rich glycoprotein in vascular homeostasis and angiogenesis.
Acta Med Okayama. , 75(6): 671-675, 2021.
Yamazaki Y, Wake H, Nishinaka T, Hatipoglu OF, Liu K, Watanabe M, Toyomura T, Mori S, Yoshino T, Nishibori M, Takahashi H.
Involvement of multiple scavenger receptors in advanced glycation end product-induced vessel tube formation in endothelial cells.
Exp Cell Res ., 408(1): 112857, 2021.
Tsubota M, Miyazaki T, Ikeda Y, Hayashi Y, Aokiba Y, Tomita S, Sekiguchi F, Wang D, Nishibori M, Kawabata A.
Caspase-dependent HMGB1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice.
Cells , 10(10): 2550, 2021.
Volmari A, Foelsch K, Zierz E, Yan K, Qi M, Bartels K, Kondratowicz S, Boettcher M, Reimers D, Nishibori M, Liu K, Schwabe RF, Lohse AW, Huber S, Mittruecker HW, Huebener P.
Leukocyte-derived high-mobility group box 1 governs hepatic immune responses to listeria monocytogenes.
Hepatol Commun ., 5(12): 2104-2120, 2021.
Namba T, Tsuge M, Yashiro M, Saito Y, Liu K, Nishibori M, Morishima T, Tsukahara H.
Anti-high mobility group box 1 monoclonal antibody suppressed hyper-permeability and cytokine production in human pulmonary endothelial cells infected with influenza A virus.
Inflamm Res ., 70(10-12): 1101-1111, 2021.
Masai K, Kuroda K, Isooka N, Kikuoka R, Murakami S, Kamimai S, Wang D, Liu K, Miyazaki I, Nishibori M, Asanuma M.
Neuroprotective effects of anti-high mobility group box-1 monoclonal antibody against methamphetamine-induced dopaminergic neurotoxicity.
Neurotox Res ., 39(5): 1511-1523, 2021.
Nakata K, Okazaki M, Shimizu D, Suzawa K, Shien K, Miyoshi K, Otani S, Yamamoto H, Sugimoto S, Yamane M, Ousaka D, Ohara T, Matsukawa A, Nishibori M, Toyooka S.
Protective effects of anti-HMGB1 monoclonal antibody on lung ischemia reperfusion injury in mice.
Biochem Biophys Res Commun ., 573: 164-170, 2021.
Araki K, Kinoshita R, Tomonobu N, Gohara Y, Tomida S, Takahashi Y, Senoo S,Taniguchi A, Itano J, Yamamoto KI, Murata H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Ichimura K, Nishibori M, Miyahara N, Toyooka S, Sakaguchi M.
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
J Mol Med (Berl) . 99(1): 131-145, 2021.
Zhu Y, Uezono N, Yasui T, Nakajo M, Nagai T, Wang D, Nishibori M, Nakashima K.
Combinatrial treatment of anti-High Mobility Group Box-1 monoclonal antibody and epothilone B improves functional recovery after spinal cord contusion injury.
Neurosci Res ., 172: 13-25, 2021.
Zhang Y, Ideguchi H, Yamashiro K, Yamamoto T, Nishibori M, Takashiba S.
Malnutrition delayed wound healing after tooth extraction by HMGB1-related prolonged inflammation.
Int Immunopharmacol ., 96: 107772, 2021.
Kuroda K, Ishii K, Mihara Y, Kawanoue N, Wake H, Mori S, Yoshida M, Nishibori M, Morimatsu H.
Histidine-rich glycoprotein as a prognostic biomarker for sepsis.
Sci Rep. ,11: 10223, 2021.
Kochi T, Nakamura Y, Ma S, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Irifune M, Morioka N.
Pretreatment with High Mobility Group Box-1 Monoclonal Antibody Prevents the Onset of Trigeminal Neuropathy in Mice with a Distal Infraorbital Nerve Chronic Constriction Injury.
Molecules , 26(7): 2035, 2021.
Nishibori M, Stonestreet BS.
Understanding of COVID-19 pathology: much more attention to plasma proteins.
Front Immunol. , 12: 656099, 2021.
Nakamura Y, Fukuta A, Miyashita K, Zhang FF, Wang D, Liu K, Wake H, Hisaoka-Nakashima K, Nishibori M, Morioka N.
Perineural high-mobility group box 1 induces mechanical hypersensitivity through activation of spinal microglia: involvement of glutamate-NMDA receptor dependent mechanism in spinal dorsal horn.
Biochem Pharmacol. , 186, 114496, 2021.
Kitaura A, NishinakaT, Hamasaki S, Hatipoglu OF, Wake H, Nishibori M, Mori S, Nakao S, Takahashi H.
Advanced glycation end-products reduce lipopolysaccharide uptake by macrophages.
PLosOne. 16(1): e0245957, 2021.
Takahashi Y, Wake H, Sakaguchi M, Yoshii Y, Teshigawara K, Wang D, Nishibori M.
Histidine-rich glycoprotein stimulates human neutrophil phagocytosis and prolonged survival through CLEC1A.
J Immunol. , ji2000817, 2021.
Hatayama K, Chen RH, Hanson J, Teshigawara K, Qui J, Santoso A, Disdier C, Nakada S, Chen X, Nishibori M, Lim YP, Stonestreet BS.
High Mobility Group Box-1 and Inter-alpha Inhibitor Proteins: In vitro binding and co-localization in cerebral cortex after hypoxic-ischemic injury.
FASEB J. , 35(3): e21399, 2021.
代表的総説
西堀正洋, 和氣秀徳, 阪口政清
血漿タンパク質HRGは敗血症防止と生体恒常性維持に働く重要な因子である
日薬理誌 , 159(2): 107-111, 2024.
Nishibori M. (Commemorative Review Article for the 14th Ebashi Setsuro Award)
Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19.
J Pharmacol Sci. , 150(1): 9-20, 2022.
西堀正洋
第14回江橋節郎賞を受賞して :DAMP-antiDAMP系を標的とする創薬
日薬理誌 , 156: 1-2, 2021.
西堀正洋
抗HMGB1抗体による神経疾患とがん創薬
臨床薬理 , 52(2): 34-37, 2021.
西堀正洋, 和氣秀徳
NETs研究
循環器疾患2021(モデル動物の作製と利用)上巻 , エル・アイ・シー: 412-421, 2021.
西堀正洋, 和氣秀徳
敗血症病態の新しい理解と好中球細胞外トラップ
岡山医学会雑誌 , 133: 10-22, 2021.
和氣秀徳, 西堀正洋
血漿タンパク質histidine-rich glycoproteinの多彩な機能と敗血症マーカー・治療薬としての臨床応用
日薬理誌 , 155(3): 155-158, 2020.
西堀正洋, 谷内一彦
特集:先端的バイオ医薬品を目指した薬理学研究の新たな展開:序文
日薬理誌 , 155(3): 149, 2020.
Nishibori M, Wang D, Ousaka D, Wake H.
High mobility group box-1 and blood-brain barrier disruption.
Cells , 9(12): 2650, 2020.
Nishibori M, Mori S, Takahashi HK.
Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases.
J Pharmacol Sci. , 140(1): 94-101, 2019.
招待講演
第49回日本集中治療医学会学術集会
教育講演「敗血症における全身炎症とHMGB1の役割」
西堀正洋, 仙台, 2022.3.18
中四国敗血症治療WEB講演会(東レ・メディカル株式会社主催)
「敗血症病態の新しい理解 —血漿タンパクの重要な働きからみたPMXの展望—」
西堀正洋, 2022.1.25
日本薬理学会 第14回 江橋節郎賞 受賞講演
「炎症病態をターゲットとしたトランスレーショナルリサーチと創薬」
西堀正洋, 札幌, 2021.3.9
第1回 知の創造セミナー
「アンメット・メディカル・ニーズと創薬」
西堀正洋, 神戸(オンライン), 2021.3.6
特許
脳梗塞抑制剤
①特許第3876325号(2006/11/10登録)
西堀正洋、森秀治、髙橋英夫、友野靖子、足立尚登、劉克約
②特許第5011496号(2012/6/15登録)
足立尚登、劉克約、元木敦子、仙波和記、平賀徳人、西堀正洋
脳血管攣縮抑制剤
特許第3882090号(2006/11/24登録)
西堀正洋、森秀治、髙橋英夫、友野靖子、伊達勲、小野成紀
外傷性神経障害治療剤
特許第6154135号(2017/6/9登録)
西堀正洋、森秀治、髙橋英夫、和氣秀徳、劉克約、伊達勲、大熊佑、友野靖子
好中球活性化に起因する疾患の治療薬、治療方法及び検査方法
特許第5807937号(2015/9/18登録),US9504731 (2016/11/29登録),EP2859898(2021/3/17登録)
西堀正洋、森秀治、和氣秀徳、 橋英夫、劉克約、勅使川原匡、阪口政清
好中球活性化に起因する疾患の治療薬及び検査方法
特許第6227601号(2017/10/20登録)
西堀正洋、森秀治、和氣秀徳、髙橋英夫、劉克約、勅使川原匡、阪口政清
ヒト化抗HMGB1抗体もしくはその抗原結合性断片
特許第6247646号(2017/11/24登録),US9550825(2017/1/24登録),CN104955846(2018/12/4登録),EP2949675(2021/3/31登録)
高田賢蔵、寅嶋崇、西堀正洋
インフルエンザ治療剤
特許第6800591号(2020/11/27登録)
西堀正洋、劉克約、塚原宏一、森島恒雄、八代将登、野坂宜之、畑山一貴
抗体薬物コンジュゲート及び抗体の薬物送達のための使用
特許第6949343号(2021/9/27登録)
西堀正洋、森秀治、高尚澤、阪口政清、友野靖子
赤血球保護剤
特許第6983420号(2021/11/26登録)
西堀正洋、和氣秀徳、衷輝、森秀治、阪口政清
抗炎症作用を有する新規単クローン抗体
特許第7340192号(2023/8/30登録)
西堀正洋、森秀治、森岡祐太、和氣秀徳、友野靖子
好中球貪食能増強剤
特許第7340862号(2023/8/31登録)
西堀正洋、和氣秀徳、高橋陽平、森秀治、阪口政清
PAGE TOP
Copyright © Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences All Rights Reserved.